Elevance Health (ELV) is up about 3.29% as investors react to a stronger-than-expected first-quarter 2026 report and a guidance raise. The company posted Q1 2026 adjusted diluted EPS of $12.58 and lifted its full-year 2026 adjusted EPS outlook to at least $26.75, signaling better visibility for the rest of the year and easing concerns that had weighed on managed-care stocks amid cost-trend uncertainty. (elevancehealth.com)

Elevance reported Q1 2026 operating revenue of $49.5 billion (+1.5% year over year) and GAAP diluted EPS of $8.00. Management attributed the quarter to underlying business strength and improving claims experience, and it reiterated full-year operating cash flow guidance of at least $5.5 billion while raising adjusted EPS guidance. (elevancehealth.com)

A major headline risk remains Medicare Advantage risk-adjustment scrutiny: Elevance recorded a $935 million accrual tied to a CMS notice regarding certain historical Medicare Advantage risk-adjustment data. Even with that item in view, the market response today is largely driven by the magnitude of the guidance increase and commentary around cost actions and performance trends. (elevancehealth.com)

Investors will look for follow-through on medical cost trend management (especially in Medicaid), clarity on the timing and ultimate size of any CMS-related payments, and whether the improved performance holds as the year progresses. Updates from management’s earnings call and any future regulatory communications around the CMS matter are likely to remain key catalysts for ELV’s next move. (ir.elevancehealth.com)